Dr. Denham on Hyperprogression in Patients With NSCLC

Video

In Partnership With:

Claude Denham, MD, Baylor Medical Center, discusses the manifestation of hyperprogression in patients with non–small cell lung cancer (NSCLC) who have been treated with immunotherapy.

Claude Denham, MD, Baylor Medical Center, discusses the manifestation of hyperprogression in patients with non—small cell lung cancer (NSCLC) who have been treated with immunotherapy.

When asked whether there is enough research on hyperprogression in patients treated with immunotherapy to warrant concern, Denham explains that he has observed it, and that it is not fully understood by the oncology community. Denham recalled a patient in which he saw the trajectory of their cancer change markedly after their first dose of immunotherapy.

Hyperprogression in patients treated with immune agents is rare, but one of the challenges physicians have in patients with lung cancer is that many of them have a lot of smoking-related co-morbidities that make separating out the more non-specific inflammatory events of immune therapy with hyperprogression or autoimmune-related adverse events somewhat complicated.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
A panel of 6 experts on colorectal cancer